Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Personalized 125I Seed Interstitial Brachytherapy for Patients Aged 80 Years and Over with Early Primary High-risk Non-melanoma Skin Cancer

Author(s): Liang Yansong, Wang Juan*, Zhang Hongtao, Liu Zezhou, Su Xiaohua, Zhao Huanfen, Zhao Rongmei and Yin Jianqi

Volume 17, Issue 2, 2024

Published on: 24 November, 2023

Page: [163 - 167] Pages: 5

DOI: 10.2174/0118744710240256231103095018

Price: $65

conference banner
Abstract

Objective: The aim of this study is to explore the safety and efficacy of iodine-125 seeds interstitial brachytherapy (PISI-BT) for patients aged 80 and above with early primary high-risk non-melanoma skin cancer (NMSC).

Methods: In this retrospective single-center study, we collected and analyzed data from patients ≥ 80 years of age with early primary high-risk NMSC treated with PISI-BT between December 2003 and May 2020. Survival status, efficacy, adverse effects (AEs), cosmetic outcomes, and treatment cost were analyzed (data cut-off: November 20th, 2021).

Results: Only 9 patients met the inclusion criteria (median age, 86 years (81-90)). Five patients had an Eastern Cooperative Oncology Group (ECOG) score of 1, and allthe patients had at least one comorbidity. Six patients showed complete responseand three showed partial response, while none had stable or progressive disease. No recurrences, disease persistence, or AEs were detected during the follow-up period. After a median follow-up of 29.3 months (3-99), only two patients were alive, but the cause of death in the remaining patients was not related to NMSC. The cosmetic outcomes were excellent and good in two and four patients, respectively, while could not be evaluated in three patients. The cost (which was within the scope of medical insurance reimbursement) was acceptable.

Conclusion: PISI-BT could be an alternative treatment option in patients above 80 years old with early primary high-risk NMSC and comorbidities.

Keywords: Interstitial brachytherapy, iodine seeds, high-risk non-melanoma skin cancer, elderly, basal cell carcinoma, adverse effects.

« Previous Next »
Graphical Abstract

[1]
World Health Organization. Radiation: Ultraviolet (UV) radiation and skin cancer, Available from: http://www.who.int/uv/faq/skincancer/en/index1.html (Accessed on: 13 March 2016).
[2]
Mann, J.; Al-Niaimi, F.; Cooper, A.; Ghura, V. A national survey of Mohs micrographic surgery in the U.K. Br. J. Dermatol., 2016, 174(1), 225-227.
[http://dx.doi.org/10.1111/bjd.14090] [PMID: 26286350]
[3]
Bouhassira, J.; Bosc, R.; Greta, L.; Hersant, B.; Niddam, J.; Zehou, O.; Roudot-Thoraval, F.; Wolkenstein, P.; Meningaud, J.P. Factors associated with postoperative complications in elderly patients with skin cancer: A retrospective study of 241 patients. J. Geriatr. Oncol., 2016, 7(1), 10-14.
[http://dx.doi.org/10.1016/j.jgo.2015.11.004] [PMID: 26769145]
[4]
Patel, R.; Strimling, R.; Doggett, S.; Willoughby, M.; Miller, K.; Dardick, L.; Mafong, E. Comparison of electronic brachytherapy and Mohs micrographic surgery for the treatment of early-stage non-melanoma skin cancer: A matched pair cohort study. J. Contemp. Brachytherapy, 2017, 4, 338-344.
[http://dx.doi.org/10.5114/jcb.2017.68480]
[5]
Hoorens, I.; Batteauw, A.; Van Maele, G.; Lapiere, K.; Boone, B.; Ongenae, K. Mohs micrographic surgery for basal cell carcinoma: Evaluation of the indication criteria and predictive factors for extensive subclinical spread. Br. J. Dermatol., 2016, 174(4), 847-852.
[http://dx.doi.org/10.1111/bjd.14308] [PMID: 26595159]
[6]
Fu, T.; Aasi, S.Z.; Hollmig, S.T. Management of high-risk squamous cell carcinoma of the skin. Curr. Treat. Options Oncol., 2016, 17(7), 34.
[http://dx.doi.org/10.1007/s11864-016-0408-2] [PMID: 27262708]
[7]
Valentin, J.; Gérard, E.; Ferte, T.; Prey, S.; Dousset, L.; Dutriaux, C.; Beylot-Barry, M.; Pham-Ledard, A. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma. J. Geriatr. Oncol., 2021, 12(7), 1110-1113.
[http://dx.doi.org/10.1016/j.jgo.2021.02.026] [PMID: 33736973]
[8]
Guinot, J.L.; Rembielak, A.; Perez-Calatayud, J.; Rodríguez-Villalba, S.; Skowronek, J.; Tagliaferri, L.; Guix, B.; Gonzalez-Perez, V.; Valentini, V.; Kovacs, G. GEC-ESTRO ACROP recommendations in skin brachytherapy. Radiother. Oncol., 2018, 126(3), 377-385.
[http://dx.doi.org/10.1016/j.radonc.2018.01.013] [PMID: 29455924]
[9]
Delishaj, D.; Laliscia, C.; Manfredi, B.; Ursino, S.; Pasqualetti, F.; Lombardo, E.; Perrone, F.; Morganti, R.; Paiar, F.; Fabrini, M.G. Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: A retrospective case series. J. Contemp. Brachytherapy, 2015, 6(6), 437-444.
[http://dx.doi.org/10.5114/jcb.2015.55746] [PMID: 26816500]
[10]
Jiao, D.; Zhou, X.; Yao, Y.; Chen, J.; Lei, Q.; Ren, J.; Han, X. 125I seed implantation brachytherapy for glottic carcinoma: An experimental and clinical study. Am. J. Cancer Res., 2021, 11(4), 1321-1334.
[PMID: 33948360]
[11]
Zhang, T; Mo, Z; Duan, G 125I seed promotes apoptosis in nonsmall lung cancer cells via the p38 MAPK-MDM2-p53 signaling pathway. Front Oncol., 2021, 11, 582511.
[http://dx.doi.org/10.3389/fonc.2021.582511]
[12]
Zhang, H.; Wang, J.; Liang, Y.; Di, X.; Liu, Z.; Zhao, J.; Wang, Z.; Zhao, J.; Sui, A. 125 I seeds implantation for an elderly patient of skin squamous cell carcinomas with ulcer guided by ultrasound. J. Cancer Res. Ther., 2018, 14(7), 1660-1664.
[http://dx.doi.org/10.4103/jcrt.JCRT_1032_17] [PMID: 30589056]
[13]
Karia, P.S.; Jambusaria-Pahlajani, A.; Harrington, D.P.; Murphy, G.F.; Qureshi, A.A.; Schmults, C.D. Evaluation of American Joint Committee on Cancer, International union against cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J. Clin. Oncol., 2014, 32(4), 327-334.
[http://dx.doi.org/10.1200/JCO.2012.48.5326] [PMID: 24366933]
[14]
Flohil, S.C.; van Dorst, A.M.J.M.; Nijsten, T.; Martino Neumann, H.A.; Munte, K. Mohs micrographic surgery for basal cell carcinomas: Appropriateness of ‘Rotterdam’ criteria and predictive factors for three or more stages. J. Eur. Acad. Dermatol. Venereol., 2013, 27(10), 1228-1235.
[http://dx.doi.org/10.1111/j.1468-3083.2012.04696.x] [PMID: 23039378]
[15]
Cox, J.D.; Stetz, J.; Pajak, T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys., 1995, 31(5), 1341-1346.
[http://dx.doi.org/10.1016/0360-3016(95)00060-C] [PMID: 7713792]
[16]
Zhang, Y.; Fornes, B.; Gómez, G.; Bentoldrà, I.; Carmona, C.; Herreros, A.; Sabater, S.; Nicolás, I.; Li, Y.; Sánchez, J.; Biete, A.; Torné, A.; Ascaso, C.; Rovirosa, Á. EQD2 analyses of vaginal complications in exclusive brachytherapy for postoperative endometrial carcinoma. Cancers, 2020, 12(10), 3059.
[http://dx.doi.org/10.3390/cancers12103059] [PMID: 33092163]
[17]
Garg, M.K.; Weiss, P.; Sharma, A.K.; Gorla, G.R.; Jaggernauth, W.; Yaparpalvi, R.; DelRowe, J.; Beitler, J.J. Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation. Radiother. Oncol., 2004, 73(2), 233-236.
[http://dx.doi.org/10.1016/j.radonc.2004.04.010] [PMID: 15542171]
[18]
Jiang, P.; Baumann, R.; Dunst, J.; Geenen, M.; Siebert, F.A.; Niehoff, P.; Bertolini, J.; Druecke, D. Perioperative interstitial high-dose-rate brachytherapy for the treatment of recurrent keloids: Feasibility and early results. Int. J. Radiat. Oncol. Biol. Phys., 2016, 94(3), 532-536.
[http://dx.doi.org/10.1016/j.ijrobp.2015.11.008] [PMID: 26867882]

Rights & Permissions Print Cite
Article Metrics
16
3
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy